Here's Why You May Invest in Theravance (TBPH) Stock Now [Yahoo! Finance]
Viatris Inc. (VTRS)
Company Research
Source: Yahoo! Finance
Theravance has collaborated with Viatris VTRS for the commercialization of Yupelri, as a once-daily, nebulized treatment of chronic obstructive pulmonary disease (COPD) in the United States. Here are some reasons why investors should consider betting on Theravance stock. Good Rank and Rising Estimates: Theravance currently has a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here In the past 30 days, estimates for Theravance's 2024 earnings per share have improved from breakeven to 6 cents. During the same period, earnings per share estimates for 2025 have moved up from 80 cents to 85 cents. Prioritizing Resource Allocation Toward Ampreloxetine: Theravance is prioritizing the development of ampreloxetine, a norepinephrine reuptake inhibitor, for the treatment of symptomatic nOH in patients with MSA. The FDA has granted Orphan Drug designation to ampreloxetine for the treatment of symptomatic nOH in patients with MSA. The phas
Show less
Read more
Impact Snapshot
Event Time:
VTRS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VTRS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VTRS alerts
High impacting Viatris Inc. news events
Weekly update
A roundup of the hottest topics
VTRS
News
- Viatris Named to TIME's World's Most Sustainable Companies 2024 List [Yahoo! Finance]Yahoo! Finance
- Viatris Named to TIME's World's Most Sustainable Companies 2024 ListPR Newswire
- Global Drug Device Combination Products Market 2024-2030: Trends and Growth Opportunities for Transdermal Patches, Infusion Pumps, Inhalers, and Drug Eluting Stents [Yahoo! Finance]Yahoo! Finance
- Viatris: Revenues, Debt, Valuation And Strategy Under The Microscope [Seeking Alpha]Seeking Alpha
- Theravance Bio (TBPH) Down 6.1% Since Last Earnings Report: Can It Rebound? [Yahoo! Finance]Yahoo! Finance
VTRS
Earnings
- 5/9/24 - Miss
VTRS
Sec Filings
- 6/17/24 - Form 4
- 6/13/24 - Form 144
- 6/4/24 - Form 4
- VTRS's page on the SEC website